Skip to content
Colour ful image showing medical imagery. Tablets and test tubes shown.
Lorem ipsum dolor sit amet, vix ne dolore salutandi, ne everti timeam explicari sed. Per ne mundi semper accusam, lucilius senserit at vel. An iuvaret praesent vim, nam erant dictas commune ad. An affert definitionem sit.

Recent posts

Blog Post: 12 OCTOBER 2021

Global COVID-19 IPR waiver negotiations

On 2 October 2020, South Africa and India submitted a proposal to the WTO to temporarily suspend certain provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS…

Read more
Science lab setting with plant, computer, flask and microscope

Blog Post: 11 OCTOBER 2021

Podcast: The injunction gap, proportionality and final injunctions: legislative updates in Germany

How will recent legislative updates in Germany affect patent litigation? 

Read more

All posts

Popular posts

Blog Post: 18 January 2019

Key developments in relation to new Chinese IP tribunal rule and Chinese patent law amendment

Recently, there have been some key developments in the intellectual property sphere in China that may be relevant to life sciences clients.  Below we report on the new Chinese IP tribunal rule…

Read more

Blog Post: 09 March 2020

Good faith: the (ad)venture continues

Three years after a joint venture for property investment was set up, relations between one of the shareholders, Mr Russell, and the others deteriorated. Russell resigned, and the parties started…

Read more

Blog Post: 16 April 2020

CATS out of the bag on unitary interpretation

This was a dispute about the amount payable by Teesside Gas to CATS for the right to use part of the capacity of a North Sea pipeline. Teesside Gas contracted with CATS to reserve capacity and paid a…

Read more

Blog Post: 30 March 2020

SEC urges companies applying for filing extensions to guard against increased insider-trading risks under U.S. Federal Securities Laws

In recent weeks, the U.S. Securities and Exchange Commission has implemented new relief measures for companies experiencing difficulties meeting their obligations under federal securities laws due to…

Read more

Related expertise